List of Camcevi Kit drug patents
Camcevi Kit is owned by Accord.
Camcevi Kit contains Leuprolide Mesylate.
Camcevi Kit has a total of 3 drug patents out of which 0 drug patents have expired.
Camcevi Kit was authorised for market use on 25 May, 2021.
Camcevi Kit is available in emulsion;subcutaneous dosage forms.
The generics of Camcevi Kit are possible to be released after 16 January, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10646572 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(3 years from now) | |
| US9572857 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(3 years from now) | |
| US9744207 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(3 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | May 25, 2024 |
Drugs and Companies using LEUPROLIDE MESYLATE ingredient
Market Authorisation Date: 25 May, 2021
Treatment: NA
Dosage: EMULSION;SUBCUTANEOUS
CAMCEVI KIT family patents
7
United States
2
Korea, Republic of
1
Taiwan, Province of China
1
Slovenia
1
Hong Kong
1
Australia
1
Russia
1
Denmark
1
Canada
1
Mexico
1
Spain
1
Japan
1
China
1
Brazil
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic